Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)

Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)

Abstract Background The guidelines of the American Diabetes Association and European Association for the Study of Diabetes suggest that patients with obesity type 2 diabetics and chronic kidney disease need either glucagon-like peptide 1 receptor analogues or sodium-glucose cotransporter-2 inhibitor...

Full description

Bibliographic Details
Main Authors: Ebaa Al-Ozairi, Kavita Narula, Alexander D. Miras, Etab Taghadom, Abeer El Samad, Jumana Al Kandari, Anas Alyosef, Anant Mashankar, Werd Al-Najim, Carel W. le Roux
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Trials
Subjects:
Type 1 diabetes
Obesity
Sodium-glucose cotransporter 2 inhibitor
Glucagon-like peptide 1 receptor analogue
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-024-07930-3

Internet

https://doi.org/10.1186/s13063-024-07930-3

Similar Items